Zacks.com on MSN
RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down
Recursion Pharmaceuticals RXRX reported a loss of 25 cents per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 23 cents. The company had incurred a loss of 41 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results